Literature DB >> 20850165

The pathogenesis of Rift Valley fever virus in the mouse model.

Darci R Smith1, Keith E Steele, Joshua Shamblin, Anna Honko, Joshua Johnson, Christopher Reed, Maureen Kennedy, Jennifer L Chapman, Lisa E Hensley.   

Abstract

Detailed studies describing the pathogenesis of Rift Valley fever (RVF) virus (RVFV) in the mouse model are lacking. A fully characterized small animal model of RVF is needed to evaluate potential vaccines and therapeutics. In this study, we characterized the pathogenesis of RVFV throughout the disease course in mice. Infection produced high-titer viremia and demonstrated RVFV tropism for a variety of tissue and individual cell types. Overwhelming infection of hepatocytes, accompanied by apoptosis, was a major consequence of infection. The majority of mice died or were euthanatized between days 3 and 6 postinfection with severe hepatitis. The remaining mice effectively cleared virus from the liver and blood, but exhibited neuroinvasion and developed panencephalitis. In addition, we characterized a number of other virological, clinicopathological, and histopathological features of RVFV infection in mice. The mouse model therefore mimics both the acute-onset hepatitis and delayed-onset encephalitis that are dominant features of severe human RVF. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20850165     DOI: 10.1016/j.virol.2010.08.016

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  61 in total

1.  Vascular permeability in the brain is a late pathogenic event during Rift Valley fever virus encephalitis in rats.

Authors:  Aaron W Walters; Michael R Kujawa; Joseph R Albe; Douglas S Reed; William B Klimstra; Amy L Hartman
Journal:  Virology       Date:  2018-11-02       Impact factor: 3.616

2.  In vitro and in vivo efficacy of a Rift Valley fever virus vaccine based on pseudovirus.

Authors:  Jian Ma; Ruifeng Chen; Weijin Huang; Jianhui Nie; Qiang Liu; Youchun Wang; Xiaoming Yang
Journal:  Hum Vaccin Immunother       Date:  2019-06-20       Impact factor: 3.452

3.  The genetic basis for susceptibility to Rift Valley fever disease in MBT/Pas mice.

Authors:  S Tokuda; T Z Do Valle; L Batista; D Simon-Chazottes; L Guillemot; M Bouloy; M Flamand; X Montagutelli; J-J Panthier
Journal:  Genes Immun       Date:  2015-01-08       Impact factor: 2.676

Review 4.  Hemorrhagic fever of bunyavirus etiology: disease models and progress towards new therapies.

Authors:  Brian B Gowen; Brady T Hickerson
Journal:  J Microbiol       Date:  2017-02-28       Impact factor: 3.422

5.  Rapamycin modulation of p70 S6 kinase signaling inhibits Rift Valley fever virus pathogenesis.

Authors:  Todd M Bell; Virginia Espina; Svetlana Senina; Caitlin Woodson; Ashwini Brahms; Brian Carey; Shih-Chao Lin; Lindsay Lundberg; Chelsea Pinkham; Alan Baer; Claudius Mueller; Elizabeth A Chlipala; Faye Sharman; Cynthia de la Fuente; Lance Liotta; Kylene Kehn-Hall
Journal:  Antiviral Res       Date:  2017-04-23       Impact factor: 5.970

6.  Attenuation of pathogenic Rift Valley fever virus strain through the chimeric S-segment encoding sandfly fever phlebovirus NSs or a dominant-negative PKR.

Authors:  Shoko Nishiyama; Olga A L Slack; Nandadeva Lokugamage; Terence E Hill; Terry L Juelich; Lihong Zhang; Jennifer K Smith; David Perez; Bin Gong; Alexander N Freiberg; Tetsuro Ikegami
Journal:  Virulence       Date:  2016-06-01       Impact factor: 5.882

7.  Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge.

Authors:  Kimberly A Dodd; Brian H Bird; Maureen G Metcalfe; Stuart T Nichol; César G Albariño
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

8.  Interplay between the Virus and Host in Rift Valley Fever Pathogenesis.

Authors:  Kaori Terasaki; Shinji Makino
Journal:  J Innate Immun       Date:  2015-02-27       Impact factor: 7.349

9.  Post-exposure vaccination with MP-12 lacking NSs protects mice against lethal Rift Valley fever virus challenge.

Authors:  Brian B Gowen; Kevin W Bailey; Dionna Scharton; Zachery Vest; Jonna B Westover; Ramona Skirpstunas; Tetsuro Ikegami
Journal:  Antiviral Res       Date:  2013-03-21       Impact factor: 5.970

10.  Cytokine response in mouse bone marrow derived macrophages after infection with pathogenic and non-pathogenic Rift Valley fever virus.

Authors:  Kimberly K Roberts; Terence E Hill; Melissa N Davis; Michael R Holbrook; Alexander N Freiberg
Journal:  J Gen Virol       Date:  2015-03-10       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.